The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Open accessAbstract
BACKGROUND: Reproductive-age women need effective interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection. METHODS: We conducted a randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as preexposure prophylaxis against HIV-1 infection in women in South Africa, Uganda, and Zimbabwe. HIV-1 testing was performed monthly, and plasma TFV levels were assessed quarterly. RESULTS: Of 12,320 women who were screened, 5029 were enrolled in the study. The rate of retention in the study was 91% during 5509 person-years of follow-up. A total of 312 HIV-1 infections occurred; the incidence of HIV-1 infection was 5.7 per 100 person-years. In the modified intention-to-treat analysis, the effectiveness was -49.0% with TDF (hazard ratio for infection, 1.49; 95% confidence interval [CI], 0.97 to 2.29), -4.4% with TDF-FTC (hazard ratio, 1.04; 95% CI, 0.73 to 1.49), and 14.5% with TFV gel (hazard ratio, 0.85; 95% CI, 0.61 to 1.21). In a random sample, TFV was detected in 30%, 29%, and 25% of available plasma samples from participants randomly assigned to receive TDF, TDF-FTC, and TFV gel, respectively. Independent predictors of TFV detection included being married, being older than 25 years of age, and being multiparous. Detection of TFV in plasma was negatively associated with characteristics predictive of HIV-1 acquisition. Elevations of serum creatinine levels were seen more frequently among participants randomly assigned to receive oral TDF-FTC than among those assigned to receive oral placebo (1.3% vs. 0.2%, P=0.004). We observed no significant differences in the frequencies of other adverse events. CONCLUSIONS: None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low. (Funded by the National Institutes of Health; VOICE ClinicalTrials.gov number, NCT00705679.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Adherence can be low (48), and prevention of HIV infection, especially among women, has not been demonstrated (47,49).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [48]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Preexposure Prophylaxis for HIV Infection among African Women
Damme, L. V., Corneli, A. L., Ahmed, K., Agot, K. E., Lombaard, J. J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R. N., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,633
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463
A Case-Cohort Design for Epidemiologic Cohort Studies and Disease Prevention Trials
Prentice, R. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.1 · Cited by 1,444
Tanser, F. C., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M. (2013) · Science · doi:10.1126/science.1228160 · Cited by 797
Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation
Liu, T. F., & Shafer, R. W. (2006) · Clinical Infectious Diseases · doi:10.1086/503914 · Cited by 661
Complex Surveys: A Guide to Analysis Using R
Lumley, T. (2010) · doi:10.1002/9780470580066 · Cited by 647
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 999
Initial implementation of PrEP in Zambia: health policy development and service delivery scale-up
Claassen, C. W., Mumba, D., Njelesani, M., Nyimbili, D., Mwango, L. K., Mwitumwa, M., Mubanga, E. M., Mulenga, L., Chisenga, T., Nichols, B. E., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047017 · Cited by 37
Beckham, S. W., Mantsios, A. R., Galai, N., Likindikoki, S. L., Mbwambo, J., Davis, W., & Kerrigan, D. L. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058611 · Cited by 36
Skovdal, M., Mandizvidza, P., Dzamatira, F., Maswera, R., Nyamukapa, C. A., Thomas, R., Mugurungi, O. M., & Gregson, S. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07376-5 · Cited by 36
Chen‐Charles, J., Davey, D. J., Toska, E., Seeley, J., & Bekker, L. (2025) · AIDS and Behavior · doi:10.1007/s10461-025-04656-4 · Cited by 36
Newman, P. A., Cameron, M. P., Roungprakhon, S., Tepjan, S., & Riccardo Scarpa, A. (2015) · AIDS and Behavior · doi:10.1007/s10461-015-1258-9 · Cited by 35
Modeling and Cost-Effectiveness in HIV Prevention
Wheatley, M. M., & Walensky, R. P. (2016) · Current HIV/AIDS Reports · doi:10.1007/s11904-016-0303-2 · Cited by 36
Guise, A., Albers, E. R., & Strathdee, S. A. (2016) · Addiction · doi:10.1111/add.13437 · Cited by 36
The cost‐effectiveness of multi‐purpose HIV and pregnancy prevention technologies in South Africa
Quaife, M., Terris‐Prestholt, F., Eakle, R., Escobar, M. A. C., Kilbourne‐Brook, M., Mvundura, M., Meyer‐Rath, G., Delany‐Moretlwe, S., & Vickerman, P. T. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25064 · Cited by 35
Pasipanodya, E. C., Jain, S., Sun, X., Blumenthal, J. S., Ellorin, E. E., Corado, K., Dubé, M. P., Daar, E. S., Morris, S., Moore, D. J., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy368 · Cited by 36
Effect of Depression on Adherence to Oral PrEP Among Men and Women in East Africa
Velloza, J., Baeten, J. M., Haberer, J. E., Ngure, K., Irungu, E., Mugo, N., Celum, C., Heffron, R. A., & for the Partners Demonstration Project Team (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001821 · Cited by 36
Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems
Mesquita, L., Galante, J., Nunes, R., Sarmento, B. F. C. C., & das Neves, J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11030145 · Cited by 36
Drain, P. K., Kubiak, R. W., Siriprakaisil, O., Klinbuayaem, V., Quame‐Amaglo, J., Sukrakanchana, P.-O., Tanasri, S., Punyati, P., Sirirungsi, W., Cressey, R., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz645 · Cited by 36
Medina‐Marino, A., Bezuidenhout, D., Ngwepe, P., Bezuidenhout, C., Facente, S. N., Mabandla, S., Hosek, S., Little, F., Celum, C., & Bekker, L. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25968 · Cited by 36
Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible?
Harries, A. D., Suthar, A. B., Takarinda, K. C., Tweya, H. M., Kyaw, N. T. T., Tayler‐Smith, K., & Zachariah, R. (2016) · F1000Research · doi:10.12688/f1000research.9247.1 · Cited by 36
Skovdal, M., Clausen, C. L., Mandizvidza, P., Dzamatira, F., Maswera, R., Nyamwanza, R. P., Nyamukapa, C. A., Thomas, R., & Gregson, S. (2022) · BMC Women s Health · doi:10.1186/s12905-022-01928-2 · Cited by 36
Preexposure Prophylaxis (PrEP) for HIV Prevention: The Primary Care Perspective
Conniff, J., & Evensen, A. (2016) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2016.01.150223 · Cited by 35
Kovářová, M., Swanson, M. D., Sánchez, R. I., Baker, C., Steve, J., Spagnuolo, R. A., Howell, B. J., Hazuda, D. J., & Garcia, J. V. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw042 · Cited by 36
Hall, E. W., Heneine, W., Sanchez, T., Sineath, R. C., & Sullivan, P. S. (2016) · Journal of Medical Internet Research · doi:10.2196/jmir.5713 · Cited by 32
Peitzmeier, S. M., Tomko, C. A., Wingo, E. E., Sawyer, A. L., Sherman, S. G., Glass, N. E., Beyrer, C., & Decker, M. R. (2017) · AIDS Care · doi:10.1080/09540121.2017.1300628 · Cited by 35
Fletcher, F. E., Fisher, C. B., Buchberg, M. K., Floyd, B., Hotton, A., Ehioba, A., & Donenberg, G. R. (2018) · Journal of Empirical Research on Human Research Ethics · doi:10.1177/1556264618755919 · Cited by 36
Topical Inserts: A Versatile Delivery Form for HIV Prevention
Peet, M. M., Agrahari, V., Anderson, S. M., Hanif, H., Singh, O., Thurman, A. R., Doncel, G. F., & Clark, M. R. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080374 · Cited by 35
Ngure, K., Thuo, N. B., Ogello, V., Kiptinness, C., Kamolloh, K., Burns, B., Mugo, N., Bukusi, E. A., Garrison, L. E., Baeten, J. M., et al. (2021) · Frontiers in Reproductive Health · doi:10.3389/frph.2021.637869 · Cited by 35
Mahomed, S., Garrett, N., Capparelli, E. V., Osman, F., Harkoo, I., Yende‐Zuma, N., Gengiah, T. N., Archary, D., Samsunder, N., Baxter, C., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac041 · Cited by 34
Jayakumaran, J. S., Aaron, E. Z., Gracely, E., Schriver, E., & Szep, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145670 · Cited by 35
Elevations in Serum Creatinine With Tenofovir-Based HIV Pre-Exposure Prophylaxis
Yacoub, R., Nadkarni, G. N., Weikum, D., Konstantinidis, I., Boueilh, A., Grant, R. M., Mugwanya, K. K., Baeten, J. M., & Wyatt, C. M. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000906 · Cited by 34
Robinson, J. A., Marzinke, M. A., Bakshi, R. P., Fuchs, E. J., Radebaugh, C. L., Aung, W. S., Spiegel, H. M. L., Coleman, J. S., Rohan, L. C., & Hendrix, C. W. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2016.0040 · Cited by 34
Zhao, C., Gunawardana, M., Villinger, F. J., Baum, M. M., Remedios-Chan, M., Moench, T. R., Zeitlin, L., Whaley, K. J., Bohorov, O., Smith, T. J., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02465-16 · Cited by 36
Long acting systemic HIV pre-exposure prophylaxis: an examination of the field
Lykins, W. R., Luecke, E. H., Johengen, D., van der Straten, A., & Desai, T. A. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0391-6 · Cited by 33
Zhang, C., McMahon, J. M., Simmons, J., Brown, L. L., Nash, R., & Liu, Y. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02573-x · Cited by 35
Holt, B. Y., Turpin, J. A., & Romano, J. (2021) · Frontiers in Reproductive Health · doi:10.3389/frph.2021.704841 · Cited by 34
Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya
Haberer, J. E., Mugo, N., Bukusi, E. A., Ngure, K., Kiptinness, C., Oware, K., Garrison, L. E., Musinguzi, N., Pyra, M. N., Valenzuela, S., et al. (2021) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002876 · Cited by 34
Gengiah, T. N., Karim, Q. A., Harkoo, I., Mansoor, L. E., Yende‐Zuma, N., Radebe, P., Samsunder, N., Baxter, C., Maharaj, B., Baum, M. M., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-052880 · Cited by 34
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?
Parikh, U. M., & Mellors, J. W. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000746 · Cited by 34
Clinical challenges in HIV/AIDS: Hints for advancing prevention and patient management strategies
Sued, O. G., Figueroa, M. I., & Cahn, P. E. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.016 · Cited by 32
Srinivasan, P., Moss, J. A., Gunawardana, M., Churchman, S. A., Yang, F., Dinh, C. T., Mitchell, J. M., Zhang, J., Fanter, R. K., Miller, C. S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157061 · Cited by 34
PrEP as a feature in the optimal landscape of combination HIV prevention in sub‐Saharan Africa
McGillen, J. B., Anderson, S., & Hallett, T. B. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.7.21104 · Cited by 33
Bazzi, A. R., Leech, A. A., Biancarelli, D. L., Sullivan, M. M., & Drainoni, M. (2017) · AIDS Patient Care and STDs · doi:10.1089/apc.2017.0098 · Cited by 33
Reza‐Paul, S., Lazarus, L., Maiya, R., Haldar, P., Rewari, B. B., Venugopal, M. S., Rahman, S. H. U., Venukumar, K. T., Ramaiah, M., Pasha, A., et al. (2020) · Global Public Health · doi:10.1080/17441692.2020.1724316 · Cited by 33
Donnell, D. J., Beesham, I., Welch, J. D., Heffron, R. A., Pleaner, M., Kidoguchi, L., Palanee‐Phillips, T., Ahmed, K., Baron, D., Bukusi, E. A., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(21)00048-5 · Cited by 33
Schaefer, R., Leite, P. H. A. D. C., Silva, R., Karim, Q. A., Akolo, C., Cáceres, C. F., Dourado, I., Green, K., Hettema, A., Hoornenborg, E., et al. (2021) · The Lancet HIV · doi:10.1016/s2352-3018(22)00004-2 · Cited by 35
Zhang, L., Iannuzzi, S., Chaturvedula, A., Irungu, E., Haberer, J. E., Hendrix, C. W., & von Kleist, M. (2023) · Nature Medicine · doi:10.1038/s41591-023-02615-x · Cited by 33
Page, K. A., Tsui, J. I., Maher, L., Choopanya, K., Vanichseni, S., Mock, P. A., Celum, C., & Martin, M. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000641 · Cited by 34
Hijazi, K., Cuppone, A. M., Smith, K. A., Stincarelli, M. A., Makinde, J., Falco, G. D., Hold, G. L., Shattock, R. J., Kelly, C. G., Pozzi, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131405 · Cited by 34
Mansoor, L. E., Lewis, L., Naicker, C. L., Harkoo, I., Dawood, H., Naidoo, K., Gengiah, T. N., Samsunder, N., Beesham, I., Karim, S. S. A., et al. (2022) · Journal of the International AIDS Society · doi:10.1002/jia2.25957 · Cited by 32
Keller, M. J., Mesquita, P. M. M., Marzinke, M. A., Teller, R. S., Espinoza, L., Atrio, J., Lo, Y., Frank, B., Srinivasan, S., Fredricks, D. N., et al. (2015) · AIDS · doi:10.1097/qad.0000000000000979 · Cited by 32
Abbai, N. S., Nyirenda, M., Naidoo, S., & Gita Ramjee, H. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1924-1 · Cited by 32
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women
Gulick, R. M., Wilkin, T. J., Chen, Y. Q., Landovitz, R. J., Amico, K. R., Young, A., Richardson, P., Marzinke, M. A., Hendrix, C. W., Eshleman, S. H., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0520 · Cited by 32
Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1
McPherson, T. D., Sobieszczyk, M. E., & Markowitz, M. H. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1460357 · Cited by 32
Sustained release silk fibroin discs: Antibody and protein delivery for HIV prevention
Yavuz, B., Morgan, J. L., Herrera, C., Harrington, K., Pérez-Ramírez, B., LiWang, P. J., & Kaplan, D. L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.001 · Cited by 32
Case, K. K., Gomez, G. B., & Hallett, T. B. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25390 · Cited by 32
Nakasone, S. E., Chimbindi, N., Mthiyane, N., Nkosi, B., Zuma, T., Baisley, K. J., Dreyer, J., Pillay, D., Floyd, S., Birdthistle, I. J., et al. (2020) · AIDS Research and Therapy · doi:10.1186/s12981-020-00310-2 · Cited by 32
Cheu, R. K., Gustin, A. T., Lee, C. Y., Schifanella, L., Miller, C. J., Ha, A., Kim, C., Rodriguez, V. J., Fischl, M. A., Burgener, A., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1009024 · Cited by 32
HIV Pathogenesis in the Human Female Reproductive Tract
Rodríguez‐García, M., Connors, K. A., & Ghosh, M. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00546-1 · Cited by 36
Rao, A., Mhlophe, H., Comins, C. A., Young, K., Mcingana, M., Lesko, C. R., Mulumba, N., Baral, S., Hausler, H., & Schwartz, S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265434 · Cited by 31
Dobard, C., Peet, M. M., Nishiura, K., Holder, A. N., Dinh, C. T., Mitchell, J. M., Khalil, G., Pan, Y., Singh, O., McCormick, T. J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104361 · Cited by 33
MOFENSON, L. M. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002133 · Cited by 31
Eakle, R., Bourne, A. H., Jarrett, C., Stadler, J., & Larson, H. J. (2017) · BMC Public Health · doi:10.1186/s12889-017-4959-3 · Cited by 32
Longino, A. A., Montaño, M. A., Sánchez, H., Bayer, A. M., Sánchez, J., Tossas, K. Y., Duerr, A. C., & Molina, Y. (2019) · AIDS Care · doi:10.1080/09540121.2019.1634787 · Cited by 31
Vickerman, P. T., Quaife, M., Kilbourne‐Brook, M., Mvundura, M., Eakle, R., & Terris‐Prestholt, F. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05399-4 · Cited by 31
Beesham, I., Heffron, R. A., Evans, S. M., Baeten, J. M., Smit, J. A., Beksinska, M. E., & Mansoor, L. E. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-03072-0 · Cited by 31
Chimbindi, N., Mthiyane, N., Zuma, T., Baisley, K. J., Pillay, D., McGrath, N. M., Harling, G., Sherr, L., Birdthistle, I. J., Floyd, S., et al. (2021) · AIDS Care · doi:10.1080/09540121.2021.1902933 · Cited by 30
Teleshova, N., Keller, M. J., Romero, J. A. F., Friedland, B., Creasy, G. W., Plagianos, M. G., Ray, L., Barnable, P., Kizima, L., Rodríguez, A., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0261775 · Cited by 31
John, S. A., Zapata, J. P., Dang, M., Pleuhs, B., O’Neil, A. M., Hirshfield, S., Walsh, J. L., Petroll, A. E., & Quinn, K. G. (2023) · Scientific Reports · doi:10.1038/s41598-023-32014-8 · Cited by 31
Balkus, J. E., Brown, E. R., Palanee‐Phillips, T., Kiweewa, F. M., Mgodi, N. M., Naidoo, L., Mbilizi, Y., Jeenarain, N., Gaffoor, Z., Siva, S. S., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001556 · Cited by 31
McClelland, R. S., Richardson, B. A., Cherutich, P., Mandaliya, K. N., John-Stewart, G. C., Miregwa, B., Odem‐Davis, K., Jaoko, W. G., Kimanga, D. O., & Overbaugh, J. M. (2015) · AIDS · doi:10.1097/qad.0000000000000829 · Cited by 29
Srinivasan, P., Zhang, J., Martin, A. M., Kelley, K., McNicholl, J. M., Buckheit, R. W., Smith, J. M., & Ham, A. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00082-16 · Cited by 30
Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How
Davies, O., Ustianowski, A., & Fox, J. (2016) · Infectious Diseases and Therapy · doi:10.1007/s40121-016-0128-8 · Cited by 29
Adolescent pre-exposure prophylaxis for HIV prevention: current perspectives
Machado, D. M., Carvalho, A. M., & Riera, R. (2017) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s112757 · Cited by 30
Bedoya, L. M., Beltrán, M., Calderón, P. O., García‐Pérez, J., Tarazona, E. D. L. T., Gonzàlez, N., Pérez‐Olmeda, M., Auñón, D., Capa, L., Gómez-Acebo, E., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001283 · Cited by 31
Carley, T., Siewert, E., & Naresh, A. (2019) · AIDS and Behavior · doi:10.1007/s10461-019-02529-1 · Cited by 29
Cheng, C., Quaife, M., Eakle, R., Escobar, M. A. C., Vickerman, P. T., & Terris‐Prestholt, F. (2019) · BMC Public Health · doi:10.1186/s12889-019-7276-1 · Cited by 29
Skovdal, M. (2019) · Journal of the International AIDS Society · doi:10.1002/jia2.25294 · Cited by 30
Nunes, R., Bogas, S., Faria, M. J., Gonçalves, H., Lúcio, M., Viseu, T. M. R., Sarmento, B. F. C. C., & das Neves, J. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.003 · Cited by 29
Cassidy, T., Ntuli, N., Kilani, C., Malabi, N., Rorwana, B., Mutseyekwa, T., O’Connell, R., Steele, S. J., Ndlovu, Z., Ellman, T., et al. (2021) · AIDS and Behavior · doi:10.1007/s10461-021-03366-x · Cited by 29
Philbin, M. M., & Perez‐Brumer, A. (2022) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000723 · Cited by 29
The current status of the use of oral medication to prevent HIV transmission
Mayer, K. H., & Gita Ramjee, H. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000170 · Cited by 29
Bunge, K. E., Dezzutti, C. S., Hendrix, C. W., Marzinke, M. A., Spiegel, H. M. L., Moncla, B. J., Schwartz, J. L., Meyn, L. A., Richardson‐Harman, N., Rohan, L. C., et al. (2018) · Journal of the International AIDS Society · doi:10.1002/jia2.25156 · Cited by 29
Past, Present, and Future Drug Delivery Systems for Antiretrovirals
Kirtane, A. R., Langer, R., & Traverso, G. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.09.015 · Cited by 28
Palanee‐Phillips, T., Schwartz, K. D., Brown, E. R., Govender, V., Mgodi, N. M., Kiweewa, F. M., Nair, G., Mhlanga, F., Siva, S. S., Bekker, L., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128857 · Cited by 28
Doggett, E. G., Lanham, M., Wilcher, R., Gafos, M., Karim, Q. A., & Heise, L. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.1.20536 · Cited by 29
Promise and pitfalls of pre-exposure prophylaxis for female sex workers
Cowan, F. M., & Delany‐Moretlwe, S. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000215 · Cited by 27
Progress and Perspectives on HIV-1 microbicide development
Alexandre, K. B., Mufhandu, H. T., London, G. M., Chakauya, E., & Khati, M. (2016) · Virology · doi:10.1016/j.virol.2016.07.004 · Cited by 30
Assessment of HIV Screening Tests for Pre-Exposure Prophylaxis Programs
Delaugerre, C., Antoni, G., Mahjoub, N., Pialoux, G., Cua, É., Pasquet, A., Hall, N., Tremblay, C. L., Cotte, L., Capitant, C., et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix297 · Cited by 28
Weighing the Evidence of Efficacy of Oral PrEP for HIV Prevention in Women in Southern Africa
Janes, H., Corey, L., Ramjee, G., Carpp, L. N., Lombard, C. J., Cohen, M. S., Gilbert, P. B., & Gray, G. (2018) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0031 · Cited by 28
Stankevitz, K., Schwartz, K. D., Hoke, T., Li, Y., Lanham, M., Mahaka, I. C., & Mullick, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218556 · Cited by 28
PrEP 1.0 and Beyond: Optimizing a Biobehavioral Intervention
Mayer, K., & Allan-Blitz, L. (2019) · Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002169 · Cited by 24
Liégeon, G., Antoni, G., Pialoux, G., Capitant, C., Cotte, L., Charreau, I., Tremblay, C. L., Cua, É., Senneville, E., Raffi, F., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25420 · Cited by 28
Impact of Medicaid Expansion on PrEP Utilization in the US: 2012–2018
Karletsos, D., & Stoecker, C. (2020) · AIDS and Behavior · doi:10.1007/s10461-020-03070-2 · Cited by 28
Long-acting capsid inhibitor protects macaques from repeat SHIV challenges
Vidal, S. J., Bekerman, E., Hansen, D., Lu, B., Wang, K., Mwangi, J. W., Rowe, W., Campigotto, F., Zheng, J., Kato, D., et al. (2021) · Nature · doi:10.1038/s41586-021-04279-4 · Cited by 29
Groves, A. K., Gebrekristos, L. T., Smith, P. D., Stoebenau, K., Stoner, M. C. D., Ameyan, W., & Ezeh, A. (2022) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2021.12.012 · Cited by 29
Matthews, R. P., Zang, X., Barrett, S. E., Koynov, A. A., Goodey, A. P., Heimbach, T., Weissler, V. L., Leyssens, C., Reynders, T., Xu, Q., et al. (2022) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003135 · Cited by 28
Friend, D. R. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1134485 · Cited by 28
Doblecki‐Lewis, S., Lester, L., Schwartz, B. N., Collins, C., Johnson, R., & Kobetz, E. K. (2015) · International Journal of STD & AIDS · doi:10.1177/0956462415601304 · Cited by 28
García‐Broncano, P., Diez, R. C., de la Mata, F. J., Gómez, R., Resino, S., & Muñoz‐Fernández, M. Á. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.060 · Cited by 28
Taiwan guideline on oral pre-exposure prophylaxis for HIV prevention – 2018 update
Chu, I. Y., Ku, S. W., Li, C., Toh, H. S., Yang, C., Wu, K.-S., Wu, H., Chen, S.-S., Kuo, J.-H., Lin, H.-H., et al. (2019) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2019.09.003 · Cited by 28
Wang, Y., Noël‐Romas, L., Perner, M., Knodel, S., Molatlhegi, R. P., Hoger, S., Birse, K., Zuend, C. F., McKinnon, L. R., & Burgener, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac938 · Cited by 29
Little, K. M., Hanif, H., Anderson, S. M., Clark, M. R., Gustafson, K., & Doncel, G. F. (2023) · AIDS and Behavior · doi:10.1007/s10461-023-04202-0 · Cited by 27
Gita Ramjee, H., Moonsamy, S., Abbai, N. S., & Wand, H. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153969 · Cited by 27
Mitchell, K. M., Prudden, H. J., Washington, R., Isac, S. K., Rajaram, S. P., Foss, A. M., Terris‐Prestholt, F., Boily, M., & Vickerman, P. T. (2016) · Journal of the International AIDS Society · doi:10.7448/ias.19.1.20942 · Cited by 27
Robinson, J. A., Marzinke, M. A., Fuchs, E. J., Bakshi, R. P., Spiegel, H. M. L., Coleman, J. S., Rohan, L. C., & Hendrix, C. W. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001587 · Cited by 28
Metadata
- Authors
- Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., Hendrix, C. W., Dai, J. Y., Ganesh, S., Mkhize, B., Taljaard, M., Parikh, U. M., Piper, J., Mâsse, B., Grossman, C., Rooney, J., Schwartz, J. L., Watts, H., Marzinke, M. A., Hillier, S. L., McGowan, I. M., & Chirenje, Z. M.
- Affiliations
- University of California, San Francisco (US)
- Harborview Medical Center (US)
- Family Health International 360 (US)
- University of Zimbabwe (ZW)
- Centre for the AIDS Programme of Research in South Africa (ZA)
- University of Pittsburgh (US)
- Johns Hopkins University (US)
- South African Medical Research Council (ZA)
- National Institutes of Health (US)
- Eastern Virginia Medical School (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-02-05
- Volume
- 372
- Issue
- 6
- Pages
- 509-518
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4341965
- OpenAlex
- W2044369525
- Cited by
- 1,296
- References
- 19
- Citations by year
- 2026: 32 · 2025: 54 · 2024: 59 · 2023: 78 · 2022: 93 · 2021: 143 · 2020: 125 · 2019: 139 · 2018: 122 · 2017: 140 · 2016: 175 · 2015: 131
- FWCI
- 147.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ResearchSpace (University of KwaZulu-Natal) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U01AI068633, UM1AI068615, UM1AI069422, UM1AI106707, UM1AI069436, P30AI094189, UM1AI069530, UM1AI069463, UM1AI069469)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- tenofovir disoproxil fumarate, tenofovir/emtricitabine, HIV pre-exposure prophylaxis, HIV-1 prevention, women, women of reproductive age, antiretroviral resistance, tenofovir resistance, drug safety, adverse events, creatinine elevation
- MeSH terms
- Emtricitabine, Tenofovir, Adenine, Administration, Intravaginal, Administration, Oral, Adolescent, Adult, Deoxycytidine, Drug Therapy, Combination, Female, HIV Seropositivity, Humans, Middle Aged, Surveys and Questionnaires, HIV-1, HIV Infections, Africa South of the Sahara, Drug Resistance, Viral, Anti-Retroviral Agents, Medication Adherence, Young Adult, Organophosphonates, Pre-Exposure Prophylaxis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
